Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Vascular Disrupting Agent ASA404 Fails in First Line Phase III Trial for Advanced NSCLC
Author
Howard (Jack) West, MD

Unfortunately, yesterday brought bad news in the form of another negative phase III trial for advanced NSCLC, this one the ATTRACT-1 trial of carboplatin/taxol (paclitaxel) with or without ASA404, which is in a class of drugs called "vascular disrupting agents" that I described in a post back in 2007. There had been a phase II trial of this combination with ASA404 that looked very promising, with a median overall survival of 14 months for the combination arm, vs. only 9 months for the arm getting chemo alone. This led to a couple of larger, more definitive studies that have been ongoing. The first, ATTRACT-1, was in the first line setting, and as noted above gave ASA404 on a backbone of carbo/taxol, and has completed enrollment. The second, ATTRACT-2, is still accruing patients and is giving taxotere (docetaxel) with or without ASA404 in the second line setting.

The news yesterday was that the ATTRACT-1 trial is being halted (no more treatment with the study drug, and people are no longer required to adhere to treatment according to the protocol-based plan), because an interim analysis of the trial results showed that the investigational arm wasn't doing any better than the standard chemo arm, and it appeared that there was no way for this to improve to the point at which ASA404 would confer a survival benefit. We don't have more details available than that, though this was enough information to lead shares of the UK-based company Antisoma, who make ASA-404, to lose 2/3 of its value over the day. Novartis had been co-developing the drug with Antisoma.

My understanding is that at the present time the second line trial is ongoing and is planned to continue to accrue patients, though I have to imagine that the enthusiasm for the concept is much lower right now that the first line trial is being abandoned. Moreover, when the CEO of Antisome says, "We have to say it's quite unlikely that we will get any future cash flows from this programme", that doesn't exactly motivate people to enroll on the sister trial.

We certainly need to learn more about the trial and whether there may be subsets of patients who did better with ASA404, but if there is something to learn from the experience, I think I would highlight that this was an example of a very glowing press release about supposed breakthrough results from a phase II trial. Here's what I said in my post from 2007:

They call it a “positive trial”, which is really a wording I’d reserve for a larger phase III trial that can actually detect differences between one treatment and another, and I would consider it rather aggressive to make an international declaration of the astounding benefit of their drug based on a phase II trial. Many new drugs and combinations show phenomenal results in small phase II trials reported early, and many don’t pan out. This doesn’t mean I don’t think the results are encouraging — I absolutely do, and I’d consider this agent on my “ones to watch” list for years to come.

I wish ASA404 had been the exception and not the rule, because we could certainly use more effective agents for lung cancer. I would have been very happy to have had my skepticism been misguided. But unfortunately, we've seen this before, and we'll see it happen again. I'd encourage people to be hopeful, because all of our positive trials were preceded by encouraging early work in smaller studies, but unfortunately many breathless press releases turn out to be more sizzle than steak.

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on